A 28-year-old woman from Delhi presents with recurrent episodes of muscle pain, weakness, and dark urine after exercise or fasting. Serum creatine kinase is markedly elevated (8000 U/L). Muscle biopsy shows lipid accumulation. Genetic testing reveals a mutation in the carnitine palmitoyltransferase II (CPT II) gene. During an acute attack, her serum lactate is only mildly elevated (3.5 mmol/L), but her blood glucose is low (50 mg/dL). Which TCA cycle intermediate is most likely depleted during her acute crisis, and why?

Explanation

## Pathophysiology of CPT II Deficiency and TCA Cycle Depletion ### Role of CPT II in Fatty Acid Oxidation Carnitine palmitoyltransferase II (CPT II) catalyzes the transfer of long-chain fatty acyl groups from carnitine back to CoA inside the mitochondrial matrix, enabling β-oxidation. CPT II deficiency blocks fatty acid entry into mitochondria, preventing: - β-oxidation and acetyl-CoA generation from fats - ATP production from lipid catabolism - Alanine and glucose synthesis during fasting ### Why Oxaloacetate Is Depleted ```mermaid flowchart TD A[Fasting State]:::outcome --> B[CPT II Deficiency]:::urgent B --> C[Fatty acid oxidation blocked]:::urgent C --> D[No acetyl-CoA from β-oxidation]:::urgent D --> E[TCA cycle slows]:::action E --> F[Oxaloacetate production ↓]:::urgent F --> G[Gluconeogenesis substrate depleted]:::urgent G --> H[Hypoglycemia]:::urgent F --> I[Cannot regenerate oxaloacetate<br/>from pyruvate]:::urgent I --> J[TCA cycle further impaired]:::urgent K[Muscle protein catabolism<br/>for alanine] --> L[Pyruvate]:::outcome L --> M{Oxaloacetate available?}:::decision M -->|No| N[Pyruvate accumulates<br/>or enters lactate]:::action M -->|Yes| O[Gluconeogenesis proceeds]:::action ``` ### The Metabolic Crisis in CPT II Deficiency **Key Point:** CPT II deficiency creates a dual crisis: 1. **Loss of fatty acid oxidation** → no acetyl-CoA from lipids → TCA cycle slowed 2. **Oxaloacetate depletion** → impaired gluconeogenesis → severe hypoglycemia During fasting or exercise: - Muscle relies on fatty acid oxidation, but CPT II is defective - Glycogen is rapidly depleted - Gluconeogenesis requires oxaloacetate (the first TCA intermediate and gluconeogenic substrate) - With TCA cycle slowed (due to lack of acetyl-CoA from fats), oxaloacetate production decreases - Pyruvate from muscle protein breakdown cannot be efficiently converted to glucose - Severe hypoglycemia results **Clinical Pearl:** Unlike mitochondrial myopathies (e.g., Complex II deficiency), CPT II deficiency does NOT cause lactic acidosis during acute attacks because: - Pyruvate is not being generated in excess (glycolysis is normal) - The problem is substrate availability for gluconeogenesis, not NAD+ regeneration - Lactate remains only mildly elevated because the block is upstream of glycolysis ### Why Oxaloacetate Specifically? Oxaloacetate is the critical hub: - **TCA cycle:** Regenerated by malate dehydrogenase; required to condense with acetyl-CoA - **Gluconeogenesis:** Converted to phosphoenolpyruvate (PEP) by PEPCK; the first committed step - **Alanine synthesis:** Transaminated from pyruvate; requires oxaloacetate as the α-ketoacid acceptor When oxaloacetate is depleted: - TCA cycle cannot turn efficiently (no substrate for citrate synthase) - Gluconeogenesis stalls (no PEP production) - Hypoglycemia ensues **High-Yield:** The hypoglycemia in CPT II deficiency is due to oxaloacetate depletion and impaired gluconeogenesis, NOT due to glycogen depletion alone. This is why glucose infusion is therapeutic. ### Why the Other Options Are Wrong | Option | Why Wrong | |--------|----------| | **Acetyl-CoA (Option 0)** | Acetyl-CoA is actually produced in excess during CPT II deficiency because carbohydrates are still oxidized and amino acids can be catabolized. The problem is not acetyl-CoA deficiency but rather inability to use it efficiently due to oxaloacetate depletion. | | **Succinyl-CoA (Option 2)** | Succinyl-CoA depletion would cause a different pattern (e.g., methylmalonic aciduria in methylmalonyl-CoA mutase deficiency). In CPT II deficiency, the TCA cycle is slowed but not blocked at succinyl-CoA. | | **Citrate (Option 3)** | Citrate depletion would occur if acetyl-CoA were abundant but oxaloacetate were depleted (which is true), but citrate is not the rate-limiting intermediate. Oxaloacetate is the bottleneck because it is both a TCA intermediate AND a gluconeogenic substrate. | ## Summary CPT II deficiency → blocked fatty acid oxidation → ↓ acetyl-CoA from lipids → ↓ TCA cycle flux → **oxaloacetate depletion** → impaired gluconeogenesis → severe hypoglycemia. Oxaloacetate is the critical intermediate linking the TCA cycle to glucose synthesis.